Abschlussbericht Für Vorhaben 3609S30013

Total Page:16

File Type:pdf, Size:1020Kb

Abschlussbericht Für Vorhaben 3609S30013 Ressortforschungsberichte zur kerntechnischen Sicherheit und zum Strahlenschutz Untersuchungen zum Zusammenwirken umweltbedingter Risikofaktoren mit genetischen und weiteren endogenen Faktoren bei der Entstehung von Leukämie im Kindesalter Teilvorhaben 1; Pilotstudie: Sequenzierung und bioinformatische Auswertung - Vorhaben 3611S70014 Auftragnehmer: Universitätsklinikum Schleswig-Holstein - Campus Kiel M. Stanulla A. Borkhardt C. Eckert J. Korbel M. Schrappe M.-L. Yaspo A. Franke Das Vorhaben wurde mit Mitteln des Bundesministeriums für Umwelt, Naturschutz, Bau und Reaktorsicherheit (BMUB) und im Auftrag des Bundesamtes für Strahlenschutz (BfS) durchgeführt. Dieser Band enthält einen Ergebnisbericht eines vom Bundesamt für Strahlenschutz im Rahmen der Ressortforschung des BMUB (UFOPLAN) in Auftrag gegebenen Untersuchungsvorhabens. Verantwortlich für den Inhalt sind allein die Autoren. Das BfS übernimmt keine Gewähr für die Richtigkeit, die Genauigkeit und Vollständigkeit der Angaben sowie die Beachtung privater Rechte Dritter. Der Auftraggeber behält sich alle Rechte vor. Insbesondere darf dieser Bericht nur mit seiner Zustimmung ganz oder teilweise vervielfältigt werden. Der Bericht gibt die Auffassung und Meinung des Auftragnehmers wieder und muss nicht mit der des BfS übereinstimmen. BfS-RESFOR-103/15 Bitte beziehen Sie sich beim Zitieren dieses Dokumentes immer auf folgende URN: urn:nbn:de:0221-2015012912280 Salzgitter, Januar 2015 - 1 - Untersuchungen zum Zusammenwirken umweltbedingter Risikofaktoren mit genetischen und weiteren endogenen Faktoren bei der Entstehung von Leukämie im Kindesalter - 2 - Pilotstudie: Sequenzierung und bioinformatische Auswertung von kindlichen Leukämie-Fällen (Akute lymphoblastische Leukämie/ALL) Martin Stanulla,1 Arndt Borkhardt,2 Cornelia Eckert,3 Jan Korbel,4 Martin Schrappe,1 Marie-Laure Yaspo,5 Andre Franke6 1 Klinik für Allgemeine Pädiatrie, Universitätsklinikum Schleswig Holstein, Campus Kiel, und Christian Albrechts Universität zu Kiel, 24105 Kiel; 2 Klinik für Kinder-Onkologie, -Hämatologie und Klinische Immunologie, Universitätsklinikum Düsseldorf, 40225 Düsseldorf; 3 Klinik für Pädiatrie mit Schwerpunkt Onkologie und Hämatologie, Charité Universi­ tätsmedizin, 13353 Berlin; 4 European Molecular Biology Laboratory (EMBL), 69117 Heidelberg; 5 Max Planck Institut für Molekulare Genetik, 14195 Berlin; 6 Institut für Klinische Molekularbiologie und 8Medizinische Klinik I, Universitätsklini- kum Schleswig Holstein, Campus Kiel, und Christian Albrechts Universität zu Kiel, 24105 Kiel - 3 - Inhalt: Seite A Zusammenfassung/Summary 4 B Projekthintergrund 8 C Methoden 34 D Ergebnisse 45 E Diskussion 74 F Literatur 79 G Anhang 91 - 4 - A Zusammenfassung/Summary Die akute lymphoblastische Leukämie (ALL) ist eine bösartige Erkrankung des Knochenmarks, bei der lymphoide Vorläuferzellen in einem frühen Differenzierungsstadium in ihrer Ausreifung blockiert sind. Die Ursachen, die der ALL zugrunde liegen, sind zum überwiegenden Teil nicht bekannt. Nur ein kleiner Prozentsatz der Fälle ist durch vererbbare genetische Prädisposition erklärbar, wie sie sich etwa für das Down-Syndrom und weitere Erkrankungen beschrieben findet. Diesen genetischen Konstellationen höherer Penetranz stehen seit kurzem auch erste Informationen aus genomweiten Assoziationsstudien gegenüber, in denen gewöhnliche Varianten in den Genen IKZF1, ARIDB5, CEBPE, TP63, PTPRJ, PIP4K2 und GATA3 mit dem Risiko einer ALL assoziiert werden konnten. Weiterhin sind zahlreiche somatische genetische Aberrationen der ALL charakterisiert worden und es kommen ständig neue hinzu. Auch zur Sequenz des Erwerbs solcher genetischer Veränderungen ist dazugelernt worden. Aus molekularen Untersuchungen an zum Neugeborenen-Screening archivierten Guthrie-Karten von eineiigen, später an ALL erkrankten Zwillingen konnte durch das Auffinden identischer Genfusionssequenzen leukämiespezifischer chromosomaler Translokationen (z.B. ETV6-RUNX1) rückgeschlossen werden, dass die ersten leukämieassoziierten genetischen Veränderungen sehr früh – nämlich bereits in utero – erworben werden können. Das Muster der letztlich in der klinisch apparenten Leukämie angesammelten genetischen Veränderungen lässt sich dabei nicht immer logisch ableiten. Seit kurzer Zeit ist es durch den enormen technischen Fortschritt im Bereich neuer Sequenzier-technologien möglich, das gesamte Erbgut auf seinen verschiedenen Ebenen zu analysieren. Diese Technologie sollte im vorliegenden Projekt an zehn ausgewählten ALLs systematisch angewendet werden, um Veränderungen des Genoms, des Exoms, des Transkriptoms, des Methyloms und des miRNoms in umfassender Art und Weise zu analysieren. Für die Analysen sind fünf B-Zell-Vorläufer- ALLs mit einer chromosomalen Translokation t(17;19), die zu einer Genfusion des Hepatic leukemia factor (HLF)-Gens mit dem TCF3-Gen führt, sowie fünf B-Zell-Vorläufer-ALLs mit einer chromosomalen Translokation t(1;19), die zu einer Genfusion des Pre-B cell leukemic homeobox1 (PBX1)-Gens mit dem TCF3­ - 5 - Gen führt, ausgewählt worden. Weiterhin sind rekurrente somatische Veränderungen, die in den initialen Sequenzieranalysen detektiert wurden, in weiteren ALL-Patientenproben validiert worden. Es wurden Read-Alignments für Genome und Exome gegen das humane Referenzgenom und Annotation und Klassifizierung der Varianten durchgeführt. Strukturelle Varianten wurden mittels Sequenzpaaranalyse, Sequenztiefenanalyse, Sequenzaufspaltungsanalyse und Sequenzassemblierung untersucht. Methylomdaten wurden mittels spezieller Algorithmen, unter Berücksichtigung der Bisulfitkonvertierung, auf die Zielregion im Referenzgenom („restriction specific target enrichment“) abgebildet - anschließend wurde der Grad der DNA-Methylierung an Cytosin-Basen bestimmt. Transkriptomsequenzen wurden nach Kartierung auf das Referenzgenom analysiert, es wurden Expressionsprofile und Pathwayanalysen für jede Probe durchgeführt sowie neben Sequenzvarianten auch eine umfassende Analyse der Spleißvarianten. TCF3-HLF-positive ALLs zeichneten sich in diesen Analysen durch eine Häufung an strukturellen Aberrationen betreffend Gene mit Bedeutung für die lymphoide Differenzierung und aktivierende RAS-Signalweg-Mutationen aus, die in TCF3­ PBX1-positiven ALLs nahezu abwesend waren. Weiterhin zeichnete sich die TCF3­ HLF-positive ALL durch eine stammzellnahe Trankriptsignatur gegenüber der TCF3­ PBX1-positiven ALL aus. In beiden Gruppen konnten Aberrationen des nicht- translozierten TCF3-Allels detektiert werden. Eine dieser Aberrationen war eine Einzelnukleotidvariante, die in weiterführenden Analysen als seltenes, rekurrentes Merkmal der ALL im Kindesalter neu beschrieben werden konnte. Insgesamt lassen diese Ergebnisse erkennen, dass neue Sequenziertechnologien detaillierte Einblicke in das Zusammenspiel molekularer Aberration bei der ALL im Kindesalters erlauben und damit eine Grundlage für ein besseres Verständnis ihrer Pathobiologie und die Entwicklung neuer, stärker individuell ausgerichteter Therapieansätze schaffen . Acute lymphoblastic leukemia (ALL) is a malignant disease of the bone marrow, characterized by an early-stage differentiation block of lymphoid progenitor cells. For the most part, causes of ALL are unknown. Only a small percentage of cases can be explained by heritable genetic predisposition, as it is described for Down's syndrome - 6 - and other diseases. This genetic constellation of higher penetrance was recently complemented with information from genome-wide association studies. These studies decribed common variants in the genes IKZF1, ARIDB5, CEBPE, TP63, PTPRJ, PIP4K2, and GATA3 to be associated with the risk of ALL. Furthermore, numerous somatic genetic aberrations of ALL have been characterized. Also, in which sequence genetic changes are acquired has been learned. Molecular studies on Guthrie cards in identical twins later diagnosed with ALL demonstrated identical sequences at chromosomal translocation breakpoints (e.g., ETV6-RUNX1). Through this, it could be inferred that the first leukemia-associated genetic changes occur already in utero. The pattern of accumulated lesions in the clinically apparent leukemia, however, often cannot be logically deduced. Recently, by the enormous technical progress in the field of new sequencing technologies, it became possible to analyze the entire genome at its various levels. In the present project, this technology was applied to systematically and comprehensively analyze ten selected ALLs for changes in the genome, exome, transcriptome, methylome, and miRNom. Five B-cell precursor ALLs with a chromosomal translocation t(17;19), leading to a gene fusion of hepatic leukemia factor (HLF) with TCF3, and five B-cell precursors ALLs with a chromosomal translocation t(1;19), leading to a gene fusion of the pre-B homeobox 1 (PBX1) gene with TCF3 gene, were selected. Furthermore, recurrent somatic changes detected in the initial sequencing analyses were validated in additional ALL patient samples. Initially, read alignments were performed for genomes and exomes against human genome reference data, nucleotide variants were annotated and classified. Structural variants were examined by paired-end, read depth, split-read, and sequence assembly analyses. Methylome data were mapped to target regions of the reference genome by means of special algorithms taking into account the bisulfate conversion ("restriction specific target enrichment"). This was followed by determination of the degree of DNA methylation at cytosine bases. Transcriptome sequences
Recommended publications
  • Genome-Wide Association Study of Behavioral Disinhibition in a Selected Adolescent Sample Jaime Derringer *, Robin P. Corley
    Genome-wide association study of behavioral disinhibition in a selected adolescent sample Jaime Derringer1*, Robin P. Corley2, Brett C. Haberstick2, Susan E. Young2, Brittany Demmitt2, Daniel P. Howrigan3, Robert M. Kirkpatrick4, William G. Iacono5, Matt McGue5, Matthew Keller2, Sandra Brown6, Susan Tapert6, Christian J. Hopfer7, Michael C. Stallings2, Thomas J. Crowley7, Soo Hyun Rhee2, Ken Krauter2, John K. Hewitt2, Matthew B. McQueen2 1 University of Illinois Urbana-Champaign, 2 University of Colorado Boulder, 3 Massachusetts General Hospital/Harvard Medical School, 4 Virginia Commonwealth University, 5 University of Minnesota, 6 University of California San Diego, 7 University of Colorado Denver * Corresponding Author: Jaime Derringer, [email protected], Department of Psychology, University of Illinois Urbana-Champaign, Champaign IL USA 61820 Behavioral disinhibition GWAS 2 Abstract Behavioral disinhibition (BD) is a quantitative measure designed to capture the heritable variation encompassing risky and impulsive behaviors. As a result, BD represents an ideal target for discovering genetic loci that predispose individuals to a wide range of antisocial behaviors and substance misuse that together represent a large cost to society as a whole. Published genome-wide association studies (GWAS) have examined specific phenotypes that fall under the umbrella of BD (e.g. alcohol dependence, conduct disorder); however no GWAS has specifically examined the overall BD construct. We conducted a GWAS of BD using a sample of 1,901 adolescents over-selected for characteristics that define high BD, such as substance and antisocial behavior problems, finding no individual locus that surpassed genome-wide significance. Although no single SNP was significantly associated with BD, restricted maximum likelihood analysis estimated that 49.3% of the variance in BD within the Caucasian sub-sample was accounted for by the genotyped SNPs (p=0.06).
    [Show full text]
  • Molecular Characterization of Acute Myeloid Leukemia by Next Generation Sequencing: Identification of Novel Biomarkers and Targets of Personalized Therapies
    Alma Mater Studiorum – Università di Bologna Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale Dottorato di Ricerca in Oncologia, Ematologia e Patologia XXX Ciclo Settore Scientifico Disciplinare: MED/15 Settore Concorsuale:06/D3 Molecular characterization of acute myeloid leukemia by Next Generation Sequencing: identification of novel biomarkers and targets of personalized therapies Presentata da: Antonella Padella Coordinatore Prof. Pier-Luigi Lollini Supervisore: Prof. Giovanni Martinelli Esame finale anno 2018 Abstract Acute myeloid leukemia (AML) is a hematopoietic neoplasm that affects myeloid progenitor cells and it is one of the malignancies best studied by next generation sequencing (NGS), showing a highly heterogeneous genetic background. The aim of the study was to characterize the molecular landscape of 2 subgroups of AML patients carrying either chromosomal number alterations (i.e. aneuploidy) or rare fusion genes. We performed whole exome sequencing and we integrated the mutational data with transcriptomic and copy number analysis. We identified the cell cycle, the protein degradation, response to reactive oxygen species, energy metabolism and biosynthetic process as the pathways mostly targeted by alterations in aneuploid AML. Moreover, we identified a 3-gene expression signature including RAD50, PLK1 and CDC20 that characterize this subgroup. Taking advantage of RNA sequencing we aimed at the discovery of novel and rare gene fusions. We detected 9 rare chimeric transcripts, of which partner genes were transcription factors (ZEB2, BCL11B and MAFK) or tumor suppressors (SAV1 and PUF60) rarely translocated across cancer types. Moreover, we detected cryptic events hiding the loss of NF1 and WT1, two recurrently altered genes in AML. Finally, we explored the oncogenic potential of the ZEB2-BCL11B fusion, which revealed no transforming ability in vitro.
    [Show full text]
  • TAS2R20 Variants Confer Dietary Adaptation to High-Quercitrin Bamboo Leaves in Qinling Giant Pandas
    TAS2R20 variants confer dietary adaptation to high-quercitrin bamboo leaves in Qinling giant pandas Xiangxu Hu1, Guan Wang2, Lei Shan3, Shuyan Sun1, Yibo Hu1, and Fuwen Wei1 1Institute of Zoology Chinese Academy of Sciences 2Affiliation not available 3Nanjing Normal University College of Life Sciences May 5, 2020 Abstract Abstract: Sensitivity to bitter tastes provides animals with an important means of interacting with their environment and thus, influences their dietary preferences. Genetic variants encoding functionally distinct receptor types contribute to variation in bitter taste sensitivity. Our previous study showed that two nonsynonymous sites, A52V and Q296H, in the TAS2R20 gene are directionally selected in giant pandas from the Qinling Mountains, which are speculated to be the causative base-pair changes of Qinling pandas for the higher preference for bamboo leaves in comparison with other pandas. Here, we used functional expression in engineered cells to identify agonists of pTAS2R20 (i.e. giant panda's TAS2R20) and interrogated the differences in perception in the in vitro responses of pTAS2R20 variants to the agonists. Our results show that pTAS2R20 is specifically activated by quercitrin and that pTAS2R20 variants exhibit differences in the sensitivity of their response to the agonist. Compared to pTAS2R20 in pandas from other areas, the receptor variant with A52V and Q296H, which is most commonly found in Qinling pandas, confers a significantly decreased sensitivity to quercitrin. We subsequently quantified the quercitrin content of the leaves of bamboo distributed in the Qinling Mountains, which was found to be significantly higher than that of the leaves of bamboo from panda habitats in other areas.
    [Show full text]
  • Supplementary Table S4. FGA Co-Expressed Gene List in LUAD
    Supplementary Table S4. FGA co-expressed gene list in LUAD tumors Symbol R Locus Description FGG 0.919 4q28 fibrinogen gamma chain FGL1 0.635 8p22 fibrinogen-like 1 SLC7A2 0.536 8p22 solute carrier family 7 (cationic amino acid transporter, y+ system), member 2 DUSP4 0.521 8p12-p11 dual specificity phosphatase 4 HAL 0.51 12q22-q24.1histidine ammonia-lyase PDE4D 0.499 5q12 phosphodiesterase 4D, cAMP-specific FURIN 0.497 15q26.1 furin (paired basic amino acid cleaving enzyme) CPS1 0.49 2q35 carbamoyl-phosphate synthase 1, mitochondrial TESC 0.478 12q24.22 tescalcin INHA 0.465 2q35 inhibin, alpha S100P 0.461 4p16 S100 calcium binding protein P VPS37A 0.447 8p22 vacuolar protein sorting 37 homolog A (S. cerevisiae) SLC16A14 0.447 2q36.3 solute carrier family 16, member 14 PPARGC1A 0.443 4p15.1 peroxisome proliferator-activated receptor gamma, coactivator 1 alpha SIK1 0.435 21q22.3 salt-inducible kinase 1 IRS2 0.434 13q34 insulin receptor substrate 2 RND1 0.433 12q12 Rho family GTPase 1 HGD 0.433 3q13.33 homogentisate 1,2-dioxygenase PTP4A1 0.432 6q12 protein tyrosine phosphatase type IVA, member 1 C8orf4 0.428 8p11.2 chromosome 8 open reading frame 4 DDC 0.427 7p12.2 dopa decarboxylase (aromatic L-amino acid decarboxylase) TACC2 0.427 10q26 transforming, acidic coiled-coil containing protein 2 MUC13 0.422 3q21.2 mucin 13, cell surface associated C5 0.412 9q33-q34 complement component 5 NR4A2 0.412 2q22-q23 nuclear receptor subfamily 4, group A, member 2 EYS 0.411 6q12 eyes shut homolog (Drosophila) GPX2 0.406 14q24.1 glutathione peroxidase
    [Show full text]
  • Reyna Alejandra Jiménez Flores
    TESIS DOCTORAL Actividad citotóxica del éter-lípido edelfosina en células de cáncer de hígado. Reyna Alejandra Jiménez Flores Director de tesis: Faustino Mollinedo García CENTRO DE INVESTIGACIÓN DEL CÁNCER UNIVERSIDAD DE SALAMANCA – CSIC SALAMANCA 2015 El Dr. Faustino Mollinedo García, Profesor de Investigación del Consejo Superior de Investigaciones Científicas (CSIC) y miembro del Instituto de Biología Molecular y Celular del Cáncer de la Universidad de Salamanca. CERTIFICA: Que la memoria de tesis titulada “Actividad citotoxica del éter‐lípido edelfosina en células de cáncer de hígado” presentado por Dña. Reyna Alejandra Jiménez Flores, ha sido realizada bajo su dirección en el Instituto de Biología Molecular y Celular del Cáncer y reúne, a su juicio, originalidad y contenidos suficientes para que sea presentada ante el tribunal correspondiente y optar al grado de Doctor por la Universidad de Salamanca. Y para que así conste, a efectos legales, expide el presente certificado en Salamanca, a 16 de noviembre de 2015. Dr. Faustino Mollinedo García Director de la tesis A mis padres y a mi hermana A Paula y a David FIDES No te resignes antes de perder definitiva, irrevocablemente La batalla que libras. Lucha erguido y sin contar las enemigas huestes. ¡Mientras veas resquicios de esperanza, no te rindas!. La suerte gusta de acumular los imposibles para vencerlos en conjunto, siempre, con el fatal y misterioso golpe de su masa de Hércules.... ¿Sabes tu si el instante en que, ya fatigado, desesperes, es justo aquel que a la definitiva realización de tu ideal precede?. Quien alienta una fe tenaz, al hado más torvo compromete en su favor.
    [Show full text]
  • Supplementary Tables Supplemental Table S1: Comparison of the Coverage of Reference Panels Used for SNP Imputation. the Markers
    Supplementary Tables Supplemental Table S1: Comparison of the coverage of reference panels used for SNP imputation. The markers on the Consortium on Asthma among African-ancestry Populations in the Americas (CAAPA) reference panel and Haplotype Reference Consortium (HRG) used to impute SNPs from our AA and CAU participants were compared to one thousand genomes (1kG) dataset. Loci information CAAPA vs 1kG HRC vs 1kG Total loci 45,639,158 90,558,388 Overlapping loci 24,880,301 49,826,569 Percent overlap 54.52% 55.02% 1kG-only loci 9,363,544 15,148,191 Ref-only loci 8,461,186 22,649,501 Supplemental Table S2: SNP imputation results. The total number of SNPs imputed for the AA and CAU participants either using the Michigan imputation server (Minimac) or Beagle. Targets prepared for: AA CAU Beagle 730,616 726,165 Minimac 698,343 660,733 Supplemental Table S3: Allele frequencies of TA2R38 SNPs by each ancestral group and time point. The rs number of each SNP, the location of SNP buy chromosome (CHR) and base pair position (POS) is provided along with the allele frequency (ALLELE:FREQ) for each SNP. Baseline 6-month Baseline 6-month AA (N = 297) AA (N = 234) CAU (N = 198) CAU (N = 151) SNP CHR POS ALLELE:FREQ ALLELE:FREQ ALLELE:FREQ ALLELE:FREQ rs10246939 7 141672604 T:0.49 C:0.51 T:0.50 C:0.50 T:0.54 C:0.46 T:0.54 C:0.46 rs1726866 7 141672705 G:0.68 A:0.32 G:0.68 A:0.32 G:0.46 A:0.54 G:0.46 A:0.54 rs713598 7 141673345 C:0.50 G:0.50 C:0.50 G:0.50 C:0.58 G:0.42 C:0.58 G:0.42 Supplemental Table S4: Linkage disequilibrium analysis of TAS2R38 SNPs at each time point of the intervention.
    [Show full text]
  • G Protein-Coupled Receptors
    S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2015/16: G protein-coupled receptors. British Journal of Pharmacology (2015) 172, 5744–5869 THE CONCISE GUIDE TO PHARMACOLOGY 2015/16: G protein-coupled receptors Stephen PH Alexander1, Anthony P Davenport2, Eamonn Kelly3, Neil Marrion3, John A Peters4, Helen E Benson5, Elena Faccenda5, Adam J Pawson5, Joanna L Sharman5, Christopher Southan5, Jamie A Davies5 and CGTP Collaborators 1School of Biomedical Sciences, University of Nottingham Medical School, Nottingham, NG7 2UH, UK, 2Clinical Pharmacology Unit, University of Cambridge, Cambridge, CB2 0QQ, UK, 3School of Physiology and Pharmacology, University of Bristol, Bristol, BS8 1TD, UK, 4Neuroscience Division, Medical Education Institute, Ninewells Hospital and Medical School, University of Dundee, Dundee, DD1 9SY, UK, 5Centre for Integrative Physiology, University of Edinburgh, Edinburgh, EH8 9XD, UK Abstract The Concise Guide to PHARMACOLOGY 2015/16 provides concise overviews of the key properties of over 1750 human drug targets with their pharmacology, plus links to an open access knowledgebase of drug targets and their ligands (www.guidetopharmacology.org), which provides more detailed views of target and ligand properties. The full contents can be found at http://onlinelibrary.wiley.com/doi/ 10.1111/bph.13348/full. G protein-coupled receptors are one of the eight major pharmacological targets into which the Guide is divided, with the others being: ligand-gated ion channels, voltage-gated ion channels, other ion channels, nuclear hormone receptors, catalytic receptors, enzymes and transporters. These are presented with nomenclature guidance and summary information on the best available pharmacological tools, alongside key references and suggestions for further reading.
    [Show full text]
  • G Protein‐Coupled Receptors
    S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2019/20: G protein-coupled receptors. British Journal of Pharmacology (2019) 176, S21–S141 THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: G protein-coupled receptors Stephen PH Alexander1 , Arthur Christopoulos2 , Anthony P Davenport3 , Eamonn Kelly4, Alistair Mathie5 , John A Peters6 , Emma L Veale5 ,JaneFArmstrong7 , Elena Faccenda7 ,SimonDHarding7 ,AdamJPawson7 , Joanna L Sharman7 , Christopher Southan7 , Jamie A Davies7 and CGTP Collaborators 1School of Life Sciences, University of Nottingham Medical School, Nottingham, NG7 2UH, UK 2Monash Institute of Pharmaceutical Sciences and Department of Pharmacology, Monash University, Parkville, Victoria 3052, Australia 3Clinical Pharmacology Unit, University of Cambridge, Cambridge, CB2 0QQ, UK 4School of Physiology, Pharmacology and Neuroscience, University of Bristol, Bristol, BS8 1TD, UK 5Medway School of Pharmacy, The Universities of Greenwich and Kent at Medway, Anson Building, Central Avenue, Chatham Maritime, Chatham, Kent, ME4 4TB, UK 6Neuroscience Division, Medical Education Institute, Ninewells Hospital and Medical School, University of Dundee, Dundee, DD1 9SY, UK 7Centre for Discovery Brain Sciences, University of Edinburgh, Edinburgh, EH8 9XD, UK Abstract The Concise Guide to PHARMACOLOGY 2019/20 is the fourth in this series of biennial publications. The Concise Guide provides concise overviews of the key properties of nearly 1800 human drug targets with an emphasis on selective pharmacology (where available), plus links to the open access knowledgebase source of drug targets and their ligands (www.guidetopharmacology.org), which provides more detailed views of target and ligand properties. Although the Concise Guide represents approximately 400 pages, the material presented is substantially reduced compared to information and links presented on the website.
    [Show full text]
  • Misexpression of Cancer/Testis (Ct) Genes in Tumor Cells and the Potential Role of Dream Complex and the Retinoblastoma Protein Rb in Soma-To-Germline Transformation
    Michigan Technological University Digital Commons @ Michigan Tech Dissertations, Master's Theses and Master's Reports 2019 MISEXPRESSION OF CANCER/TESTIS (CT) GENES IN TUMOR CELLS AND THE POTENTIAL ROLE OF DREAM COMPLEX AND THE RETINOBLASTOMA PROTEIN RB IN SOMA-TO-GERMLINE TRANSFORMATION SABHA M. ALHEWAT Michigan Technological University, [email protected] Copyright 2019 SABHA M. ALHEWAT Recommended Citation ALHEWAT, SABHA M., "MISEXPRESSION OF CANCER/TESTIS (CT) GENES IN TUMOR CELLS AND THE POTENTIAL ROLE OF DREAM COMPLEX AND THE RETINOBLASTOMA PROTEIN RB IN SOMA-TO- GERMLINE TRANSFORMATION", Open Access Master's Thesis, Michigan Technological University, 2019. https://doi.org/10.37099/mtu.dc.etdr/933 Follow this and additional works at: https://digitalcommons.mtu.edu/etdr Part of the Cancer Biology Commons, and the Cell Biology Commons MISEXPRESSION OF CANCER/TESTIS (CT) GENES IN TUMOR CELLS AND THE POTENTIAL ROLE OF DREAM COMPLEX AND THE RETINOBLASTOMA PROTEIN RB IN SOMA-TO-GERMLINE TRANSFORMATION By Sabha Salem Alhewati A THESIS Submitted in partial fulfillment of the requirements for the degree of MASTER OF SCIENCE In Biological Sciences MICHIGAN TECHNOLOGICAL UNIVERSITY 2019 © 2019 Sabha Alhewati This thesis has been approved in partial fulfillment of the requirements for the Degree of MASTER OF SCIENCE in Biological Sciences. Department of Biological Sciences Thesis Advisor: Paul Goetsch. Committee Member: Ebenezer Tumban. Committee Member: Zhiying Shan. Department Chair: Chandrashekhar Joshi. Table of Contents List of figures .......................................................................................................................v
    [Show full text]
  • Bivariate Genome-Wide Association Analysis Strengthens the Role of Bitter Receptor Clusters on Chromosomes 7 and 12 in Human Bitter Taste
    bioRxiv preprint doi: https://doi.org/10.1101/296269; this version posted April 6, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Bivariate genome-wide association analysis strengthens the role of bitter receptor clusters on chromosomes 7 and 12 in human bitter taste Liang-Dar Hwang1,2,3,4, Puya Gharahkhani1, Paul A. S. Breslin5,6, Scott D. Gordon1, Gu Zhu1, Nicholas G. Martin1, Danielle R. Reed5, and Margaret J. Wright2,7 1 QIMR Berghofer Medical Research Institute, Herston, Queensland 4006, Australia 2 Queensland Brain Institute, University of Queensland, St Lucia, Queensland 4072, Australia 3 Faculty of Medicine, University of Queensland, Herston, Queensland 4006, Australia 4 University of Queensland Diamantina Institute, University of Queensland, Translational Research Institute, Woolloongabba, Queensland 4102, Australia 5 Monell Chemical Senses Center, Philadelphia, Pennsylvania 19104, USA 6 Department of Nutritional Sciences, School of Environmental and Biological Sciences, Rutgers University, New Brunswick NJ, 08901 USA 7 Centre for Advanced Imaging, University of Queensland, St Lucia, Queensland 4072, Australia Correspondence to be sent to: Liang-Dar Hwang University of Queensland Diamantina Institute Wolloongabba QLD 4102, Australia Email: [email protected] Telephone: +61 7 3443 7976 Fax: +61 7 3443 6966 1 bioRxiv preprint doi: https://doi.org/10.1101/296269; this version posted April 6, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
    [Show full text]
  • Differentially Methylated Genes
    10/30/2013 Disclosures Key Rheumatoid Arthritis-Associated Pathogenic Pathways Revealed by Integrative Analysis of RA Omics Datasets Consultant: IGNYTA Funding: Rheumatology Research Foundation By John W. Whitaker, Wei Wang and Gary S. Firestein DNA methylation and gene regulation The RA methylation signature in FLS DNA methylation – DNMT1 (maintaining methylation) OA – DNMT3a, 3b (de novo methylation) RA % of CpG methylation: 0% 100% Nakano et al. 2013 ARD AA06 AANAT AARS ABCA6 ABCC12 ABCG1 ABHD8 ABL2 ABR ABRA ACACA ACAN ACAP3 ACCSL ACN9 ACOT7 ACOX2 ACP5 ACP6 ACPP ACSL1 ACSL3 ACSM5 ACVRL1 ADAM10 ADAM32 ADAM33 ADAMTS12 ADAMTS15 ADAMTS19 ADAMTS4 ADAT3 ADCK4 ADCK5 ADCY2 ADCY3 ADCY6 ADORA1 ADPGK ADPRHL1 ADTRP AFAP1 AFAP1L2 AFF3 AFG3L1P AGAP11 AGER AGTR1 AGXT AIF1L AIM2 AIRE AJUBA AK4 AKAP12 AKAP2 AKR1C2 AKR1E2 AKT2 ALAS1 ALDH1L1-AS1 ALDH3A1 ALDH3B1 ALDH8A1 ALDOB ALDOC ALOX12 ALPK3 ALS2CL ALX4 AMBRA1 AMPD2 AMPD3 ANGPT1 ANGPT2 ANGPTL5 ANGPTL6 ANK1 ANKMY2 ANKRD29 ANKRD37 ANKRD53 ANO3 ANO6 ANO7 ANP32C ANXA6 ANXA8L2 AP1G1 AP2A2 AP2M1 AP5B1 APBA2 APC APCDD1 APOBEC3B APOBEC3G APOC1 APOH APOL6 APOLD1 APOM AQP1 AQP10 AQP6 AQP9 ARAP1 ARHGAP24 ARHGAP42 ARHGEF19 ARHGEF25 ARHGEF3 ARHGEF37 ARHGEF7 ARL4C ARL6IP 5 ARL8B ARMC3 ARNTL2 ARPP21 ARRB1 ARSI ASAH2B ASB10 ASB2 ASCL2 ASIC4 ASPH ATF3 ATF7 ATL1 ATL3 ATP10A ATP1A1 ATP1A4 ATP2C1 ATP5A1 ATP5EP2 ATP5L2 ATP6V0CP3 ATP6V1C1 ATP6V1E2 ATXN7L1 ATXN7L2 AVPI1 AXIN2 B3GNT7 B3GNT8 B3GNTL1 BACH1 BAG3 Differential methylated genes in RA FLS BAIAP2L2 BANP BATF BATF2 BBS2 BCAS4 BCAT1 BCL7C BDKRB2 BEGAIN BEST1 BEST3
    [Show full text]
  • Transcriptome Analysis Reveals Upregulation of Bitter Taste Receptors in Severe Asthmatics
    ORIGINAL ARTICLE ASTHMA Transcriptome analysis reveals upregulation of bitter taste receptors in severe asthmatics Christina Orsmark-Pietras1,2, Anna James2,3, Jon R. Konradsen2,4,5, Bjo¨rn Nordlund2,4,5, Cilla So¨derha¨ll1,2, Ville Pulkkinen2,3,6,7, Christophe Pedroletti2,5, Kameran Daham2,8,9, Maciek Kupczyk2,3, Barbro Dahle´n2,8,9, Juha Kere1,2,10, Sven-Erik Dahle´n2,3, Gunilla Hedlin2,4,5,11 and Erik Mele´n2,3,4,11 Affiliations: 1Dept of Biosciences and Nutrition at Novum, Karolinska Institute, Stockholm, 2The Centre for Allergy Research at Karolinska Institute, Stockholm, 3Institute of Environmental Medicine, Karolinska Institute, Stockholm, 4Astrid Lindgren Children’s Hospital, Karolinska University Hospital, Stockholm, 5Dept of Women’s and Children’s Health, Karolinska Institute, Stockholm, 8Lung/Allergy Clinic, Karolinska University Hospital Huddinge, Stockholm, 9Dept of Internal Medicine, Karolinska University Hospital Huddinge, Stockholm, and 10Science for Life Laboratory, Karolinska Institute, Stockholm, Sweden. 6Dept of Medical Genetics, Biomedicum Helsinki, University of Helsinki, Helsinki, and 7Folkha¨lsan Institute of Genetics, Helsinki, Finland. 11Both authors contributed equally. Correspondence: S-E. Dahle´n, The National Institute of Environmental Medicine, Karolinska Institutet, SE- 17177 Stockholm, Sweden. E-mail: [email protected] ABSTRACT The causes of severe childhood asthma are poorly understood. Our aim was to define global patterns of gene expression in children with severe therapy-resistant and controlled asthma. White blood cells were isolated and the global transcriptome profile was characterised using the Affymetrix Human Gene ST 1.0 chip in children with severe, therapy-resistant asthma (n517), controlled asthma (n519) and healthy controls (n518).
    [Show full text]